Abstract
Human immunodeficiency virus type 1 (HIV-1) infected patients treated with combination antiretroviral therapy frequently have the level of HIV-1 RNA detectable in plasma driven below the lower limit of detection of current assays, 50 copies ml−1. Patients may continue to exhibit viral loads (VLs) below the assay limit for years, yet on some occasions the VL may be above the limit of detection. Whether these ‘blips’ in VL are simply assay errors or are indicative of intermittent episodes of increased viral replication is of great clinical concern. By analyzing the occurrence of viral blips in 123 treated HIV-infected patients, we show that patients do not share a common probability distribution of blip amplitude and thus reject the hypothesis that blips are solely due to assay variation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cohen Stuart, J. W., A. M. Wensing, C. Kovacs, M. Righart, D. de Jong, S. Kaye, R. Schuurman, C. J. Visser and C. A. Boucher (2001). Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance. J. Acquir. Immune Defic. Syndr. 28, 105–113.
Di Mascio, M., M. Markowitz, M. Louie, A. Hurley, D. D. Ho and A. S. Perelson (2002). Viral blips dynamics during HAART. IX Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
Dornadula, G. et al. (1999). Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627–1632.
Feller, W. (1968). An Introduction to Probability Theory and its Applications, 3rd edn, New York: John Wiley, p. 66.
Furtado, M. R., D. S. Callaway, J. P. Phair, K. J. Kunstman, J. L. Stanton, C. A. Macken, A. S. Perelson and S. M. Wolinsky (1999). Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614–1622.
Gulick, R. M. et al. (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734–739.
Gunthard, H. F. et al. (1999). Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73, 9404–9412.
Hammer, S. M. et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N. Engl. J. Med. 337, 725–733.
Havlir, D. V. et al. (2001). Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286, 171–179.
Hermankova, M., S. C. Ray, C. Ruff, M. Powell-Davis, R. Ingersoll, R. T. D’Aquila, T. C. Quinn, J. D. Siliciano, R. F. Siliciano and D. Persaud (2001). HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 286, 196–207.
Ho, D. D. (1998). Toward HIV eradication or remission: the tasks ahead. Science 280, 1866–1867.
Hockett, R. D., J. M. Kilby, C. A. Derdeyn, M. S. Saag, M. Sillers, K. Squires, S. Chiz, M. A. Nowak, G. M. Shaw and R. P. Bucy (1999). Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J. Exp. Med. 189, 1545–1554.
Jones, L. E. and A. S. Perelson (2002). Modeling the effects of tetanus vaccination on chronically infected HIV-1 patients. JAIDS 31, 369–377.
Mellors, J. W., C. R. Rinaldo Jr, P. Gupta, R. M. White, J. A. Todd and L. A. Kingsley (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167–1170.
Montaner, J. S. et al. (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA 279, 930–937.
Motulsky, H. (1995). Futher Analyisis of Contingency Tables. Intuitive Biostatistics, New York: Oxford University Press, pp. 250–254.
Palella, F. J. Jr, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman and S. D. Holmberg (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 338, 853–860.
Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz and D. D. Ho (1997). Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188–191.
Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard and D. D. Ho (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582–1586.
Ramratnam, B., J. E. Mittler, L. Zhang, D. Boden, A. Hurley, F. Fang, C. A. Macken, A. S. Perelson, M. Markowitz and D. D. Ho (2000). The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6, 82–85.
Sharkey, M. E. et al. (2000). Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6, 76–81.
Tucker, A. (1980). Applied Combinatorics, New York: John Wiley, p. 66.
Yerly, S., T. V. Perneger, S. Vora, B. Hirschel and L. Perrin (2000). Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 14, 2805–2812.
Zhang, L. et al. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605–1613.
Author information
Authors and Affiliations
Corresponding author
Additional information
Work performed under the auspices of the U.S. Department of Energy.
Rights and permissions
About this article
Cite this article
Percus, J.K., Percus, O.E., Markowitz, M. et al. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull. Math. Biol. 65, 263–277 (2003). https://doi.org/10.1016/S0092-8240(02)00095-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/S0092-8240(02)00095-2